As the pharmaceutical industry continues to evolve in the wake of pandemic-driven disruptions and heightened regulatory scrutiny, the role of the top pharmaceutical API manufacturer has taken on ...

Just weeks after announcing a deal to sell its antibiotics manufacturing in the U.S. to Neopharma, India’s Dr. Reddy’s Laboratories says it will now unload its API manufacturing business in Jeedimetla ...

AbbVie’s $100 billion splurge on domestic manufacturing and R&D is continuing to come into focus, this time with a $380 million investment in two new active pharmaceutical ingredient manufactur | The ...

Eli Lilly and Company (Lilly) plans to construct an active pharmaceutical ingredient (API) manufacturing facility, totaling around 1 million square feet, in Harris County, Texas. According to news ...

BioDuro, a CRDMO, has established a joint venture with Cenra API Solutions, a pharmaceutical chemical manufacturer in Taiwan.

Construction is scheduled to commence in spring 2026, with both facilities anticipated to be fully operational by 2029.

EAST RUTHERFORD, N.J., Sept. 26, 2017 (GLOBE NEWSWIRE) -- Cambrex Corporation (NYSE:CBM), the leading manufacturer of small molecule innovator and generic Active Pharmaceutical Ingredients (APIs), ...

EAST RUTHERFORD, N.J., Oct. 22, 2025 /PRNewswire/ -- Cambrex, a leading global contract development and manufacturing organization (CDMO), today announced a $120 million investment to expand its U.S.

While solely API-focused players currently face increased competition, this transition is expected to strengthen long-term pricing power, improve margins, enhance compliance, and increase customer ...

The global industry was valued at US$ 38.9 Bn in 2022 and is expected to register a CAGR of 7.1% from 2023 to 2031. Demand for biologics, biosimilars, and other biopharmaceuticals is growing at a ...